BE895080A - Procede de preparation de derives de 3-hydroxy-ml-236b connus comme m-4 et m-4' - Google Patents

Procede de preparation de derives de 3-hydroxy-ml-236b connus comme m-4 et m-4'

Info

Publication number
BE895080A
BE895080A BE0/209527A BE209527A BE895080A BE 895080 A BE895080 A BE 895080A BE 0/209527 A BE0/209527 A BE 0/209527A BE 209527 A BE209527 A BE 209527A BE 895080 A BE895080 A BE 895080A
Authority
BE
Belgium
Prior art keywords
hydroxy
preparation
derivatives known
derivatives
Prior art date
Application number
BE0/209527A
Other languages
English (en)
French (fr)
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of BE895080A publication Critical patent/BE895080A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/365—Nocardia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/872—Nocardia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pyrane Compounds (AREA)
BE0/209527A 1981-11-20 1982-11-19 Procede de preparation de derives de 3-hydroxy-ml-236b connus comme m-4 et m-4' BE895080A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56186641A JPS5889191A (ja) 1981-11-20 1981-11-20 ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法

Publications (1)

Publication Number Publication Date
BE895080A true BE895080A (fr) 1983-03-16

Family

ID=16192138

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/209527A BE895080A (fr) 1981-11-20 1982-11-19 Procede de preparation de derives de 3-hydroxy-ml-236b connus comme m-4 et m-4'

Country Status (18)

Country Link
US (1) US4537859A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS5889191A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR880002483B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) AT387585B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU551720B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE895080A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1186647A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH651065A5 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3242849A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK159328C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES8402350A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI70925C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR2516935A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB2111052B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT (1) IT1191235B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (1) NL194373C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SE (1) SE453996B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA828535B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215665B1 (en) * 1985-09-13 1991-11-21 Sankyo Company Limited Hydroxy-ml-236b derivatives, their preparation and use
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
EP0306263B1 (en) * 1987-09-02 1992-03-18 Merck & Co. Inc. Novel hmg-coa reductase inhibitors
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
EP0337548A3 (en) * 1988-04-15 1991-08-14 Merck & Co. Inc. HMG-COA reductase inhibitors produced by nocardia SP. (MA6455)(ATCC 53695)
US4997755A (en) * 1988-04-15 1991-03-05 Merck & Co., Inc. HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
US4963538A (en) * 1988-06-29 1990-10-16 Merck & Co., Inc. 5-oxygenated HMG-CoA reductase inhibitors
US4970231A (en) * 1989-06-09 1990-11-13 Merck & Co., Inc. 4-substituted HMG-CoA reductase inhibitors
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US4937259A (en) * 1989-06-09 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
US5001241A (en) * 1989-06-09 1991-03-19 Merck & Co., Inc. 3-KETO HMG-CoA reductase inhibitors
US5041562A (en) * 1989-06-09 1991-08-20 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
US4997849A (en) * 1989-06-23 1991-03-05 Merck & Co., Inc. Microbial transformation of simvastatin
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US5112857A (en) * 1990-09-04 1992-05-12 Merck & Co., Inc. Hmg-coa reductase inhibitor metabolites
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
IL108432A (en) * 1993-01-29 1997-09-30 Sankyo Co DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6043064A (en) * 1993-10-22 2000-03-28 Bristol-Myers Squibb Company Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
US5942423A (en) * 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
SI9800144A (sl) * 1998-05-21 1999-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
DE60034547T8 (de) * 1999-01-20 2008-04-30 Kyowa Hakko Kogyo Co., Ltd. Verfahren zur herstellung von hemmern der hmg-coa reduktase
JP4668420B2 (ja) * 1999-01-29 2011-04-13 協和発酵バイオ株式会社 ＨＭＧ−ＣｏＡレダクターゼ阻害剤の製造法
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
CN1468098A (zh) * 2000-10-05 2004-01-14 �ݰ¸Ƕ�ҩ�����޹�˾ 基本上无普伐他汀内酯和表普伐他汀的普伐他汀钠和包含普伐他汀钠的组合物
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
JP2005528400A (ja) * 2002-04-16 2005-09-22 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ活性を有する塩の固体形態
RU2217141C1 (ru) * 2002-11-20 2003-11-27 Балавадзе Михаил Элизбарович Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
EP1961419B1 (en) 2002-12-20 2010-03-24 Pfizer Products Inc. Dosage forms comprising a CETP inhibitor and an HMG-CoA reductase inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
KR100470078B1 (ko) * 2003-06-12 2005-02-04 씨제이 주식회사 컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Ｓｔｒｅｐｔｏｍｙｃｅｓ ｓｐ.)ＣＪＰＶ 975652 및 그를 이용한 프라바스타틴의 제조방법
AU2004266740B2 (en) 2003-08-21 2010-08-26 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
US20050101927A1 (en) * 2003-09-11 2005-05-12 Kimberly-Clark Worldwide, Inc. Absorbent products comprising a moisturizing and lubricating composition
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
TWI252253B (en) * 2004-01-09 2006-04-01 Chinese Petroleum Corp A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
US20110217412A1 (en) * 2004-07-30 2011-09-08 Jinis Biopharmaceuticals Co. Cholesterol lowering supplement and low cholesterol egg produced by using the same
KR100637762B1 (ko) * 2004-07-30 2006-10-23 주식회사 지니스 저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
TWI307360B (en) 2004-12-03 2009-03-11 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for constructing strain having compactin hydroxylation ability
JP2008523065A (ja) 2004-12-09 2008-07-03 メルク エンド カムパニー インコーポレーテッド エストロゲン受容体モジュレーター
PT1855674E (pt) 2005-03-02 2014-10-08 Merck Canada Inc Composição para a inibição de catepsina k
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
TWI387592B (zh) * 2005-08-30 2013-03-01 Novartis Ag 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
PT2010528T (pt) 2006-04-19 2017-12-21 Novartis Ag Compostos benzotiazole e benzoxazole 6-o-substituídos e métodos de inibição da sinalização csf-1r
EP2698157B1 (en) 2006-09-22 2015-05-20 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
RS51780B (en) 2007-01-10 2011-12-31 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.R.L. INDASOLS SUBSTITUTED BY AMIDE AS INHIBITORS OF POLY (ADP-Ribose) POLYMERASES (PARP)
EP2132177B1 (en) 2007-03-01 2013-07-17 Novartis AG Pim kinase inhibitors and methods of their use
ES2452349T3 (es) 2007-05-21 2014-04-01 Novartis Ag Inhibidores de CSF-1R, composiciones, y métodos de uso
JP5501227B2 (ja) 2007-06-27 2014-05-21 メルク・シャープ・アンド・ドーム・コーポレーション ヒストンデアセチラーゼ阻害剤としての４−カルボキシベンジルアミノ誘導体
WO2009082437A2 (en) 2007-12-21 2009-07-02 Ligand Pharmaceuticals Incorporated Selective androgen receptor modulators (sarms) and uses thereof
CN102016054A (zh) * 2008-04-25 2011-04-13 株式会社太平洋 用生物转化系统制备正二羟基异黄酮的方法
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
WO2011046771A1 (en) 2009-10-14 2011-04-21 Schering Corporation SUBSTITUTED PIPERIDINES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
JP2013537423A (ja) 2010-08-17 2013-10-03 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP2632472B1 (en) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2012145471A1 (en) 2011-04-21 2012-10-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
HRP20180002T1 (hr) 2012-11-28 2018-02-09 Merck Sharp & Dohme Corp. Kompozicije i postupci za liječenje karcinoma
US8846657B2 (en) 2012-12-20 2014-09-30 Merck Sharp & Dohme Corp. Substituted imidazopyridines as HDM2 inhibitors
EP2951180B1 (en) 2013-01-30 2018-05-02 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
EP3041938A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Circular polynucleotides
CA2923272A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
EP3613418A1 (en) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706742B1 (en) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5 inhibitors
WO2020033284A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033288A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12319651B2 (en) 2019-04-19 2025-06-03 Ligand Pharmaceuticals Incorporated Crystalline forms and methods of producing crystalline forms of a compound
KR20220123229A (ko) 2019-12-17 2022-09-06 머크 샤프 앤드 돔 엘엘씨 Prmt5 억제제
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3392171A (en) * 1964-03-20 1968-07-09 Upjohn Co 4-morpholino-4'-hydroxy bicyclohexyls
US3281330A (en) * 1964-03-20 1966-10-25 Upjohn Co Microbiological process for the oxygenation of cycloalkanes
MX7065E (es) * 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b

Also Published As

Publication number Publication date
DK159328C (da) 1991-02-25
NL194373C (nl) 2002-02-04
IT1191235B (it) 1988-02-24
DK516182A (da) 1983-05-21
GB2111052B (en) 1985-05-09
FI823978A0 (fi) 1982-11-19
DE3242849C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1989-01-05
AT387585B (de) 1989-02-10
DE3242849A1 (de) 1983-06-01
US4537859A (en) 1985-08-27
KR880002483B1 (ko) 1988-11-19
FI823978L (fi) 1983-05-21
DK159328B (da) 1990-10-01
CA1186647A (en) 1985-05-07
SE8206580D0 (sv) 1982-11-18
ATA425182A (de) 1988-07-15
NL8204505A (nl) 1983-06-16
JPH0371116B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1991-11-12
JPS5889191A (ja) 1983-05-27
AU551720B2 (en) 1986-05-08
CH651065A5 (de) 1985-08-30
KR840002451A (ko) 1984-07-02
GB2111052A (en) 1983-06-29
FR2516935A1 (fr) 1983-05-27
NL194373B (nl) 2001-10-01
FR2516935B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1985-02-08
FI70925C (fi) 1986-10-27
ES517542A0 (es) 1984-01-16
ZA828535B (en) 1983-10-26
FI70925B (fi) 1986-07-18
IT8268359A0 (it) 1982-11-22
SE453996B (sv) 1988-03-21
ES8402350A1 (es) 1984-01-16
AU9061082A (en) 1983-05-26
SE8206580L (sv) 1983-05-21

Similar Documents

Publication Publication Date Title
BE895080A (fr) Procede de preparation de derives de 3-hydroxy-ml-236b connus comme m-4 et m-4'
MA19639A1 (fr) Procede de preparation de derives de l'acide cis, endo-2-azabicyclo- (3,3,0) -octane-3- carboxylique et d'agents contenant ces derives
RO91184A (ro) Procedeu pentru prepararea unor derivati de 2,2'-iminobesetanol
PT75499B (fr) Procede pour la preparation de l'alkanoilanilides
RO93218A (ro) Procedeu pentru prepararea unor derivati de 2-oxindol
RO96413A (ro) Procedeu pentru prepararea unor derivati de tiadiazol
PT75209B (fr) Procede de preparation d'amidobenzamides
FR2562541B1 (fr) Procede stereocontrole de preparation d'acetoxyazetidinone
FR2565590B1 (fr) Procede de preparation d'aminohydroxycephamcarboxylates
FR2559766B1 (fr) Procede de preparation de derives de l'acide carbamique
MC1692A1 (fr) Procede de preparation de derives de phenyltetraenyle derives de phenyltetraenyle et leur application
RO93563A (ro) Procedeu de preparare a unor derivati de 3-fenoxifenil-propen-1-il-ciclopropan
FR2555578B1 (fr) Procede de preparation de derives d'azetidinone
RO87007A (ro) Procedeu si instalatie pentru prepararea izomerozei
FR2562896B1 (fr) Procede de preparation de derives de 3-exomethylenecephame
FR2560199B1 (fr) Procede de preparation de l'i-brassicasterol
FR2564833B1 (fr) Procede de preparation de derives d'imidazolidine
FR2569692B1 (fr) Procede de preparation de derives de guanidinothiazole
FR2543141B1 (fr) Procede de preparation de l'azinomethyl-rifamycine
BE886867A (fr) Procede pour la preparation de derives d'esters halogenovincaminiques et halogeno-apovincaminiques
FR2569194B3 (fr) Procede de preparation d'une aminolactone
FR2562074B1 (fr) Procede de preparation de derives de 2,2-bishalomethylpename
FR2601955B1 (fr) Procede de preparation d'alkyl et d'arylchlorosilane
FR2572072B1 (fr) Procede de preparation de derives d'indole
FR2565970B1 (fr) Procede de preparation d'aminobenzylamines